157 related articles for article (PubMed ID: 31111685)
21. Updates in prognostic markers for gliomas.
Aquilanti E; Miller J; Santagata S; Cahill DP; Brastianos PK
Neuro Oncol; 2018 Nov; 20(suppl_7):vii17-vii26. PubMed ID: 30412261
[TBL] [Abstract][Full Text] [Related]
22. Characterisation of molecular alterations in microdissected archival gliomas.
Walker C; Joyce KA; Thompson-Hehir J; Davies MP; Gibbs FE; Halliwell N; Lloyd BH; Machell Y; Roebuck MM; Salisbury J; Sibson DR; Du Plessis D; Broome J; Rossi ML
Acta Neuropathol; 2001 Apr; 101(4):321-33. PubMed ID: 11355303
[TBL] [Abstract][Full Text] [Related]
23. SOCS3 promoter methylation is mutually exclusive to EGFR amplification in gliomas and promotes glioma cell invasion through STAT3 and FAK activation.
Lindemann C; Hackmann O; Delic S; Schmidt N; Reifenberger G; Riemenschneider MJ
Acta Neuropathol; 2011 Aug; 122(2):241-51. PubMed ID: 21590492
[TBL] [Abstract][Full Text] [Related]
24. TERT promoter wild-type glioblastomas show distinct clinical features and frequent PI3K pathway mutations.
Williams EA; Miller JJ; Tummala SS; Penson T; Iafrate AJ; Juratli TA; Cahill DP
Acta Neuropathol Commun; 2018 Oct; 6(1):106. PubMed ID: 30333046
[TBL] [Abstract][Full Text] [Related]
25. SEL1L SNP rs12435998, a predictor of glioblastoma survival and response to radio-chemotherapy.
Mellai M; Cattaneo M; Storaci AM; Annovazzi L; Cassoni P; Melcarne A; De Blasio P; Schiffer D; Biunno I
Oncotarget; 2015 May; 6(14):12452-67. PubMed ID: 25948789
[TBL] [Abstract][Full Text] [Related]
26. TERT promoter mutations and telomere length in adult malignant gliomas and recurrences.
Heidenreich B; Rachakonda PS; Hosen I; Volz F; Hemminki K; Weyerbrock A; Kumar R
Oncotarget; 2015 Apr; 6(12):10617-33. PubMed ID: 25797251
[TBL] [Abstract][Full Text] [Related]
27. Pediatric Gliomas Presenting with Gliomatosis-Like Spread, Lack of Contrast Enhancement, EGFR Mutation, and TERT Promoter Variants.
Smith HL; Collins J; Park D; Darlington W; Quezado M; Aldape K; Warnke P; Pytel P
J Neuropathol Exp Neurol; 2021 Dec; 80(12):1134-1136. PubMed ID: 34524458
[No Abstract] [Full Text] [Related]
28. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A
Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844
[TBL] [Abstract][Full Text] [Related]
29. Telomerase activity-independent function of TERT allows glioma cells to attain cancer stem cell characteristics by inducing EGFR expression.
Beck S; Jin X; Sohn YW; Kim JK; Kim SH; Yin J; Pian X; Kim SC; Nam DH; Choi YJ; Kim H
Mol Cells; 2011 Jan; 31(1):9-15. PubMed ID: 21193962
[TBL] [Abstract][Full Text] [Related]
30. Molecular Diagnostic and Prognostic Subtyping of Gliomas in Tunisian Population.
Trabelsi S; Chabchoub I; Ksira I; Karmeni N; Mama N; Kanoun S; Burford A; Jury A; Mackay A; Popov S; Bouaouina N; Ben Ahmed S; Mokni M; Tlili K; Krifa H; Yacoubi MT; Jones C; Saad A; H'mida Ben Brahim D
Mol Neurobiol; 2017 May; 54(4):2381-2394. PubMed ID: 26957305
[TBL] [Abstract][Full Text] [Related]
31. Determination of EGFR status in gliomas: usefulness of immunohistochemistry and fluorescent in situ hybridization.
Guillaudeau A; Durand K; Pommepuy I; Robert S; Chaunavel A; Lacorre S; DeArmas R; Bourtoumieux S; El Demery M; Moreau JJ; Labrousse F
Appl Immunohistochem Mol Morphol; 2009 May; 17(3):220-6. PubMed ID: 19391220
[TBL] [Abstract][Full Text] [Related]
32. Subgroup characteristics of insular low-grade glioma based on clinical and molecular analysis of 42 cases.
Tang C; Zhang ZY; Chen LC; Sun Z; Zhang Y; Qin Z; Yao Y; Zhou LF
J Neurooncol; 2016 Feb; 126(3):499-507. PubMed ID: 26586262
[TBL] [Abstract][Full Text] [Related]
33. Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future.
Chen R; Cohen AL; Colman H
Curr Treat Options Oncol; 2016 Aug; 17(8):42. PubMed ID: 27334978
[TBL] [Abstract][Full Text] [Related]
34. TERT promoter mutations and long telomere length predict poor survival and radiotherapy resistance in gliomas.
Gao K; Li G; Qu Y; Wang M; Cui B; Ji M; Shi B; Hou P
Oncotarget; 2016 Feb; 7(8):8712-25. PubMed ID: 26556853
[TBL] [Abstract][Full Text] [Related]
35. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes.
Labussière M; Boisselier B; Mokhtari K; Di Stefano AL; Rahimian A; Rossetto M; Ciccarino P; Saulnier O; Paterra R; Marie Y; Finocchiaro G; Sanson M
Neurology; 2014 Sep; 83(13):1200-6. PubMed ID: 25150284
[TBL] [Abstract][Full Text] [Related]
36. A machine learning analysis of a "normal-like" IDH-WT diffuse glioma transcriptomic subgroup associated with prolonged survival reveals novel immune and neurotransmitter-related actionable targets.
Nguyen HD; Allaire A; Diamandis P; Bisaillon M; Scott MS; Richer M
BMC Med; 2020 Oct; 18(1):280. PubMed ID: 33059718
[TBL] [Abstract][Full Text] [Related]
37. Characteristics of the isocitrate dehydrogenase gene and telomerase reverse transcriptase promoter mutations in gliomas in Chinese patients.
Qu CX; Ji HM; Shi XC; Bi H; Zhai LQ; Han DW
Brain Behav; 2020 Apr; 10(4):e01583. PubMed ID: 32146731
[TBL] [Abstract][Full Text] [Related]
38. IDH1 status is significantly different between high-grade thalamic and superficial gliomas.
Zuo M; Li M; Chen N; Yu T; Kong B; Liang R; Wang X; Mao Q; Liu Y
Cancer Biomark; 2017 Aug; 20(2):183-189. PubMed ID: 28869450
[TBL] [Abstract][Full Text] [Related]
39. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
[TBL] [Abstract][Full Text] [Related]
40. Impact of proliferation index on outcome in childhood malignant gliomas: results in a multi-institutional cohort.
Pollack IF; Hamilton RL; Burnham J; Holmes EJ; Finkelstein SD; Sposto R; Yates AJ; Boyett JM; Finlay JL
Neurosurgery; 2002 Jun; 50(6):1238-44; discussion 1244-5. PubMed ID: 12015841
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
